Current Research on Identifying Biomarkers in Breast Cancer

March 21, 2018
Elizabeth Mittendorf, MD, PhD

Elizabeth Mittendorf, MD, PhD, director of the Breast Oncology Program at the Susan F. Smith Center for Women’s Cancers at Dana-Farber Cancer Institute, discusses the importance of identifying biomarkers in patients with breast cancer. Current studies are looking at PD-L1 as a possible biomarker, but Mittendorf believes there may be other biomarkers that will prove to be more reliable. 

Elizabeth Mittendorf, MD, PhD, director of the Breast Oncology Program at the Susan F. Smith Center for Women’s Cancers at Dana-Farber Cancer Institute, discusses the importance of identifying biomarkers in patients with breast cancer. Current studies are looking at PD-L1 as a possible biomarker, but Mittendorf believes there may be other biomarkers that will prove to be more reliable.

When using antibodies to target the PD-1 and PD-L1 axes, the thought has been that PD-L1 expression is important for the response, Mittendorf explains. However, PD-L1 may not be the best biomarker because it is incredibly dynamic, which may cause issues in predicting response in patients.